How genetic risk is reshaping cardiovascular prevention

In today’s cardiovascular care, prevention means more than tracking traditional risk factors. It requires anticipation. Cardiologists are now expected to not only manage risk but foresee it. Meeting that expectation calls for insights that are earlier, deeper, and more personalized than ever before.

Despite the widespread use of established risk models, many patients continue to experience preventable cardiac events. A significant number of these individuals fall outside current guideline thresholds for intervention. They represent a pattern of undetected, inherited risk that traditional models are not equipped to identify.

To intervene earlier and more precisely, clinicians need an advanced method for identifying risk before the disease develops. This is where genomic insights and polygenic risk scores (PRS) provide significant value.

Traditional risk models have limitations

Traditional risk factors, based on LDL cholesterol, blood pressure, and smoking history, form the foundation of cardiovascular risk assessment. However, they do not account for a patient’s lifelong genetic predisposition. In younger individuals, asymptomatic patients, or those with borderline markers, these models can underestimate risk.

Genetic risk operates independently of clinical presentation. Without integrating this information, many high risk individuals remain undetected until symptoms arise or adverse events occur.

PRS bridges this gap. It offers a stable, lifelong measure of genetic risk that enhances every clinical risk discussion with greater accuracy.

PRS testing in clinical decision making

A polygenic risk score aggregates the influence of hundreds of thousands of genetic variants associated with coronary artery disease. Unlike traditional risk assessments, it is unaffected by, lifestyle, or day to day fluctuations in lab results.

In practice, PRS empowers cardiologists to:

• Identify high-risk patients before standard risk factors indicate elevated risk
• Prompt earlier interventions in cases that are otherwise uncertain
• Communicate risk more effectively, leading to improved adherence and patient engagement

These are not theoretical advantages. They are clinically validated benefits with real world impact.

Allelica Multi-Ancestry CAD PRS test: Built for clinical practice

Allelica Multi-Ancestery CAD PRS testing was developed with clinical application in mind. It is a practical tool that enhances current workflows without requiring additional changes. The test offers:

• Provides accurate results across multi-ancestry populations to support inclusive care.
• Delivers easy to understand reports with clear, actionable insights that fit smoothly into your workflow.
• Fast turnaround and user friendly interpretation make it easy to use in everyday practice.

This solution integrates easily into routine clinical practice, enhancing current strategies where traditional models fall short. It empowers clinicians to detect risk earlier and take decisive action with greater precision and confidence.

Empowering clinical confidence and better outcomes

This is not a replacement for clinical judgment. It is a complementary tool that enhances it with validated, evidence based insights. It supports earlier, more confident decisions and aligns with the standards of modern preventive cardiology.

Allelica Multi-Ancestry CAD PRS delivers clarity, supports personalization, and helps change outcomes by detecting risk before it turns into disease.

To learn how this tool can be integrated into your practice, contact us at info@allelica.com.

The future of cardiovascular prevention belongs to those who recognize risk early and act with precision.